NASDAQ:BLSM

BlossomHill Therapeutics (BLSM) Stock Price, News & Analysis

BlossomHill Therapeutics logo
$14.59 -0.54 (-3.57%)
As of 04:00 PM Eastern

About BlossomHill Therapeutics Stock (NASDAQ:BLSM)

Advanced

Key Stats

Today's Range
$14.34
▼
$16.75
50-Day Range
$12.35
▼
$26.82
52-Week Range
$11.02
▼
$27.99
Volume
280,172 shs
Average Volume
205,672 shs
Market Capitalization
$463.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00
Consensus Rating
Moderate Buy

Company Overview

BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes.

The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment.

Publicly available information about the company’s leadership and geographic operations is limited.

AI Generated. May Contain Errors.

BlossomHill Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

BLSM MarketRank™: 
3.144850498335 of 5 stars

BlossomHill Therapeutics scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BlossomHill Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    BlossomHill Therapeutics has a consensus price target of $35.00, representing about 138.1% upside from its current price of $14.70.

  • Amount of Analyst Coverage

    BlossomHill Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BlossomHill Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BlossomHill Therapeutics are expected to grow in the coming year, from ($5.54) to ($3.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BlossomHill Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BlossomHill Therapeutics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.86% of the float of BlossomHill Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BlossomHill Therapeutics has a short interest ratio ("days to cover") of 4.65.
  • Change versus previous month

    Short interest in BlossomHill Therapeutics has recently increased by 21.69%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BlossomHill Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BlossomHill Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    BlossomHill Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for BlossomHill Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for BLSM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added BlossomHill Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
Receive BLSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BlossomHill Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BLSM Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

BLSM Stock Analysis - Frequently Asked Questions

BlossomHill Therapeutics' stock was trading at $16.00 on August 7, 2026. Since then, BLSM shares have decreased by 8.1% and is now trading at $14.70.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.36.

BlossomHill Therapeutics (BLSM) raised $150 million in an initial public offering on Friday, August 7th 2026. The company issued 9,375,000 shares at a price of $16.00 per share.

Shares of BLSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:BLSM
CIK
1839970
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

High Price Target
$40.00
Low Price Target
$28.00
Potential Upside/Downside
+139.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.56 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-52.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.82
Quick Ratio
12.82

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.64 per share
Price / Book
2.20

Miscellaneous

Outstanding Shares
31,780,000
Free Float
N/A
Market Cap
$463.67 million
Optionable
N/A
Beta
N/A
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:BLSM) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners